Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | -0.57 Increased by +16.18% | -0.55 Decreased by -6.61% |
| Mar 23, 23 | -0.57 Increased by +12.31% | -0.49 Decreased by -33.32% |
| Nov 8, 22 | -0.52 Increased by +30.67% | -0.55 Increased by +9.92% |
| Aug 9, 22 | -0.64 Increased by +13.51% | -0.57 Decreased by -21.55% |
| May 10, 22 | -0.68 Decreased by -4.62% | -0.59 Decreased by -25.85% |
| Mar 17, 22 | -0.65 Increased by +10.96% | -0.74 Increased by +16.44% |
| Nov 4, 21 | -0.75 Increased by +25.74% | -0.76 Increased by +1.73% |
| Aug 5, 21 | -0.74 Increased by +7.50% | -0.67 Decreased by -15.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -24.12 M Increased by +20.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 32.57 M Increased by +213.42% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -22.84 M Increased by +29.96% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -28.33 M Increased by +9.73% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -30.25 M Decreased by -12.45% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -28.72 M Decreased by -2.08% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -32.61 M Increased by +11.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -31.39 M Decreased by -8.88% | Decreased by N/A% Decreased by N/A% |
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.